Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones

被引：16
作者：
Ho, PL
Yam, WC
Que, TL
Tsang, DNC
Seto, WH
Ng, TK
Ng, WS
机构：
[1] Univ Hong Kong, Dept Microbiol, Div Infect Dis, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Sch Profess & Continuing Educ, Hong Kong, Hong Kong, Peoples R China
[4] Tuen Mun Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
[5] Queen Elizabeth Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
[6] Princess Margaret Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 47卷 / 05期
关键词：
D O I：
10.1093/jac/47.5.655
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Ciprofloxacin-susceptible (n = 7) and -resistant (MIC greater than or equal to 4 mg/L) (n = 15) clinical isolates of Streptococcus pneumoniae from diverse sources in Hong Kong were studied for target site modifications and efflux phenotype, Reserpine-inhibited efflux of ciprofloxacin and/or levofloxacin was common in both susceptible and non-susceptible isolates. The ParC substitutions K137N and/or S79F or Y were associated with increased ciprofloxacin MICs, The GyrA substitution S81F was only found in isolates with full resistance to ciprofloxacin (MIC greater than or equal to 16 mg/L) and levofloxacin (MIC greater than or equal to 8 mg/L). Among clinical isolates of S. pneumoniae, accumulation of target site mutations in strains with an efflux mechanism was associated with increasing MICs of fluoroquinolones.
引用
收藏
页码：655 / 658
页数：4
相关论文
共 9 条
[1]   Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria [J].
Andrews, JM ;
Ashby, JP ;
Jevons, GM ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :819-822
[2]   A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus:: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux [J].
Beyer, R ;
Pestova, E ;
Millichap, JJ ;
Stosor, V ;
Noskin, GA ;
Peterson, LR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :798-801
[3]   Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae [J].
Broskey, J ;
Coleman, K ;
Gwynn, MN ;
McCloskey, L ;
Traini, C ;
Voelker, L ;
Warren, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 :95-99
[4]   Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong [J].
Ho, PL ;
Que, TL ;
Tsang, DNC ;
Ng, TK ;
Chow, KH ;
Seto, WH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1310-1313
[5]   High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].
Janoir, C ;
Zeller, V ;
Kitzis, MD ;
Moreau, NJ ;
Gutmann, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764
[6]   Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season [J].
Jones, ME ;
Sahm, DF ;
Martin, N ;
Scheuring, S ;
Heisig, P ;
Thornsberry, C ;
Köhrer, K ;
Schmitz, FJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :462-466
[7]  
*NCCLS, 1999, PERF STAND ANT SUSC
[8]   Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].
Pan, XS ;
Ambler, J ;
Mehtar, S ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326
[9]   Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae [J].
Perichon, B ;
Tankovic, J ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1166-1167
1